IL128059A - Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors - Google Patents

Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors

Info

Publication number
IL128059A
IL128059A IL12805997A IL12805997A IL128059A IL 128059 A IL128059 A IL 128059A IL 12805997 A IL12805997 A IL 12805997A IL 12805997 A IL12805997 A IL 12805997A IL 128059 A IL128059 A IL 128059A
Authority
IL
Israel
Prior art keywords
angiotensin
treatment
prevention
pharmaceutical compositions
receptor antagonists
Prior art date
Application number
IL12805997A
Other languages
English (en)
Other versions
IL128059A0 (en
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Priority to IL14575897A priority Critical patent/IL145758A0/xx
Publication of IL128059A0 publication Critical patent/IL128059A0/xx
Publication of IL128059A publication Critical patent/IL128059A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12805997A 1996-07-15 1997-07-11 Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors IL128059A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14575897A IL145758A0 (en) 1996-07-15 1997-07-11 Pharmaceutical compositions for treatment and prevention of arteriosclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18436896 1996-07-15
PCT/JP1997/002407 WO1998002183A1 (en) 1996-07-15 1997-07-11 Medicinal compositions

Publications (2)

Publication Number Publication Date
IL128059A0 IL128059A0 (en) 1999-11-30
IL128059A true IL128059A (en) 2003-12-10

Family

ID=16152008

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12805997A IL128059A (en) 1996-07-15 1997-07-11 Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors
IL145758A IL145758A (en) 1996-07-15 2001-10-04 Pharmaceutical preparations for the prevention and treatment of atherosclerotic diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145758A IL145758A (en) 1996-07-15 2001-10-04 Pharmaceutical preparations for the prevention and treatment of atherosclerotic diseases

Country Status (19)

Country Link
US (1) US6610682B2 (no)
EP (2) EP1175902B1 (no)
KR (1) KR100540618B1 (no)
CN (2) CN1221259C (no)
AT (2) ATE283704T1 (no)
AU (1) AU714618B2 (no)
CA (1) CA2261040C (no)
CZ (2) CZ299162B6 (no)
DE (2) DE69734405T2 (no)
DK (2) DK0930076T3 (no)
ES (2) ES2250283T3 (no)
HK (1) HK1020260A1 (no)
HU (2) HU227399B1 (no)
IL (2) IL128059A (no)
NO (2) NO322314B1 (no)
NZ (1) NZ333723A (no)
PT (1) PT930076E (no)
RU (2) RU2183128C2 (no)
WO (1) WO1998002183A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU2382601A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel method of treatment
EP1326604A2 (en) * 2000-04-12 2003-07-16 Novartis AG Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
JP3874419B2 (ja) * 2003-01-31 2007-01-31 三共株式会社 動脈硬化及び高血圧症の予防及び治療のための医薬
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
EP1898951B1 (en) * 2005-06-27 2013-02-27 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
SG166126A1 (en) 2005-10-04 2010-11-29 Bayer Schering Pharma Ag Novel polymorphous form and the amorphous form of 5-chloro-n-({(5s)-2-oxo- 3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20090076104A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched losartan
JP5755143B2 (ja) * 2008-11-19 2015-07-29 メリアル リミテッド アリールピラゾールおよび／またはホルムアミジンを含む組成物、それらの方法ならびに使用
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN107648611A (zh) * 2017-09-18 2018-02-02 浙江大学 复方血管紧张素转换酶类抗瘢痕外用制剂
CN107617107A (zh) * 2017-09-18 2018-01-23 浙江大学 一种复方血管紧张素转换酶类抗瘢痕制剂
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231080A (en) 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3925759A1 (de) * 1989-08-03 1991-02-07 Thera Patent Verwaltungs Gmbh Verwendung von ace-inhibitoren fuer die atheroskleroseprophylaxe
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
GB2241890A (en) 1990-03-12 1991-09-18 Squibb & Sons Inc Preventing onset of or treating protein catabolism using an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
CA2229000C (en) * 1991-02-21 2002-04-09 Sankyo Company, Limited 1-biphenylimidazole derivatives, their preparation and their therapeutic use
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2118706A1 (en) * 1992-07-13 1994-01-20 Saizo Shibata Novel thiazolidinedione compounds and use thereof
WO1994019347A1 (en) * 1993-02-24 1994-09-01 Sankyo Company, Limited Arteriosclerosis remedy
JPH0741423A (ja) 1993-02-24 1995-02-10 Sankyo Co Ltd 動脈硬化症治療剤
CA2145257A1 (en) * 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
SK283348B6 (sk) 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II

Also Published As

Publication number Publication date
NZ333723A (en) 2000-09-29
CZ300089B6 (cs) 2009-01-28
DE69734405D1 (de) 2006-03-02
EP0930076A4 (en) 2001-10-04
KR100540618B1 (ko) 2006-01-12
HU0600501D0 (en) 2006-08-28
IL128059A0 (en) 1999-11-30
HU225415B1 (en) 2006-11-28
DK0930076T3 (da) 2005-01-31
EP1175902A1 (en) 2002-01-30
CN1476833A (zh) 2004-02-25
DE69731840D1 (de) 2005-01-05
ES2232873T3 (es) 2005-06-01
CA2261040A1 (en) 1998-01-22
HUP9903166A3 (en) 2003-09-29
NO20056021L (no) 1999-03-15
CA2261040C (en) 2009-01-20
KR20000023757A (ko) 2000-04-25
CZ10299A3 (cs) 1999-06-16
CZ299162B6 (cs) 2008-05-07
EP1175902B1 (en) 2005-10-19
PT930076E (pt) 2005-01-31
EP0930076B1 (en) 2004-12-01
NO322314B1 (no) 2006-09-11
ES2250283T3 (es) 2006-04-16
HK1020260A1 (en) 2000-04-07
DE69734405T2 (de) 2006-08-03
IL145758A (en) 2006-06-11
US6610682B2 (en) 2003-08-26
DE69731840T2 (de) 2005-08-04
ATE306921T1 (de) 2005-11-15
EP0930076A1 (en) 1999-07-21
RU2220723C2 (ru) 2004-01-10
CN1221259C (zh) 2005-10-05
ATE283704T1 (de) 2004-12-15
HU227399B1 (en) 2011-05-30
RU2183128C2 (ru) 2002-06-10
NO990166L (no) 1999-03-15
AU3459597A (en) 1998-02-09
US20020013308A1 (en) 2002-01-31
NO334217B1 (no) 2014-01-13
NO990166D0 (no) 1999-01-14
CN1230122A (zh) 1999-09-29
DK1175902T3 (da) 2005-12-19
CN1155409C (zh) 2004-06-30
AU714618B2 (en) 2000-01-06
WO1998002183A1 (en) 1998-01-22
HUP9903166A2 (hu) 2000-09-28
HUP0600501A3 (en) 2008-10-28

Similar Documents

Publication Publication Date Title
IL128059A (en) Pharmaceutical compositions for treatment and prevention of arteriosclerosis containing insulin resistance improving agents, angiotensin ii receptor antagonists and angiotensin converting enzyme inhibitors
IL115059A (en) Pharmaceutical composition for oral administration comprising a combination of ramipril and a dihydropyridine compound
DK0893992T3 (da) Hurtigt sönderdelende oral doseringsform
RU2001126527A (ru) Средство и способ лечения или профилактики артериосклероза
IL131084A0 (en) The use of levobupivacaine in facial surgery
GR3036071T3 (en) Use od moxonidine for the Treatment of neuropathic pain
EP1057472A4 (en) SOLID PREPARATION FOR ORAL HYGIENE
GR3030954T3 (en) Children-proof package for active substance-containing plaster
CA2269031A1 (en) Treatment of urinary incontinence and compositions for use therein
CA2551963A1 (en) Pharmaceutical compositions and treatment of arteriosclerosis with cs-866
AU7937794A (en) Use of lithium compounds for treating high blood pressure
HUP9903818A2 (hu) Transzdermális terápiás rendszer ösztriolt tartalmazó hatóanyag-kombinációval
ITRA910006A0 (it) Attrezzo di sicurezza per lo scorrimento e l'autobloccaggio di corde, singole e doppie, durante impieghi alpinistici e non.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired